Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Myomo Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Myomo şirketinin toplam hissedar öz sermayesi $9.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $16.2M ve $6.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.98m
Eşitlik	US$9.68m
Toplam yükümlülükler	US$6.51m
Toplam varlıklar	US$16.19m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0M61 'nin kısa vadeli varlıkları ( $15.1M ) kısa vadeli yükümlülüklerini ( $6.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0M61 şirketinin kısa vadeli varlıkları ( $15.1M ) uzun vadeli yükümlülüklerini ( $47.3K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0M61 borçsuzdur.

Borcun Azaltılması: 0M61 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0M61 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 0M61 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Myomo Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.036 loss in 2Q 2023)

Myomo, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Myomo, Inc. Provides Revenue Guidance for the Second Quarter Ended June 30, 2024

Lead Independent Director recently bought €162k worth of stock

Chief Medical Officer recently sold €120k worth of stock

Forecast to breakeven in 2026

Myomo, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Full year 2023 earnings released: US$0.28 loss per share (vs US$1.52 loss in FY 2022)

New minor risk - Profitability

Myomo, Inc. to Report Q1, 2024 Results on May 08, 2024

Myomo, Inc., Annual General Meeting, Jun 05, 2024

Myomo, Inc. Appoints Heather Getz as Class II Director and Chair of Audit Committee

Lead Independent Director recently bought €161k worth of stock

Forecast to breakeven in 2026

Myomo, Inc. Provides Earnings Guidance for the First Quarter of 2024

New minor risk - Market cap size

Myomo, Inc. to Report Q4, 2023 Results on Mar 15, 2024

Myomo, Inc. has filed a Follow-on Equity Offering in the amount of $6.000002 million.

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.058 loss per share (vs US$0.40 loss in 3Q 2022)

Myomo, Inc. Announces CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro for Review at the Upcoming HCPCS Public Meeting

Myomo, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Chairman recently bought €56k worth of stock

Second quarter 2023 earnings released: US$0.036 loss per share (vs US$0.42 loss in 2Q 2022)

Myomo, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Centers for Medicare and Medicaid Services Accepts Myomo, Inc.'s Application to Classify the MyoPro as A Brace

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.41 loss in 1Q 2022)

Myomo, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Myomo, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$1.52 loss per share (vs US$1.89 loss in FY 2021)

the National Disability Insurance Scheme in Australia Approves Myomo, Inc.'s MyoPro for Patient with Paralyzed Arm

Myomo, Inc. Appoints Yitzchak Jacobovitz as A Class II Director

Insufficient new directors

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 3Q 2021)

Myomo, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 and Full Year of 2023

Myomo, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.47 loss in 2Q 2021)

Myomo, Inc. Provides Revenue Guidance or Third Quarter 2022

Myomo, Inc. Provides Revenue Guidance for the Second Quarter of 202

First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.57 loss in 1Q 2021)

Myomo, Inc. to Report Q1, 2022 Results on May 11, 2022

Myomo, Inc., Annual General Meeting, Jun 08, 2022

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Myomo, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Myomo Announces MyoPro® 2+

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.70 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$1.12 loss in 2Q 2020)

No longer forecast to breakeven

First quarter 2021 earnings released: US$0.57 loss per share (vs US$2.52 loss in 1Q 2020)

Revenue beats expectations

Full year 2020 earnings released: US$3.47 loss per share (vs US$19.35 loss in FY 2019)

Myomo, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Myomo, Inc. Announces Techniker Krankenkasse Approves Reimbursement of the Company

New 90-day high: €12.10

Myomo® Forms Joint Venture to Manufacture and Sell the Company’s Products in China

New 90-day high: €9.80

Myomo Inc.'s Sublease with Upstatement, LLC Becomes Effective

New 90-day high: €7.50

Myomo, Inc. Introduces MyoGames

Revenue beats expectations

New 90-day high: €4.64

Third quarter 2020 earnings released: US$0.70 loss per share

Myomo, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Myomo, Inc. Appoints Harry Kovelman as Chief Medical Officer

New 90-day low - €2.96

Earnings released

Myomo, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - €3.02

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço